Disrupting tumour blood vessels (Q36146900)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Disrupting tumour blood vessels	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

1 reference

Europe PubMed Central

Disrupting tumour blood vessels (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

1

object named as

Gillian M Tozer

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

author name string

Chryso Kanthou

2

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Bruce C Baguley

3

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

language of work or name

0 references

publication date

1 June 2005

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Nature Reviews Cancer

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

423-435

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Studies in tissue metabolism: The action of colchicine and B. typhosus extract

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Factors determining the action of colchicine on tumour growth

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Vinca alkaloids: anti-vascular effects in a murine tumour

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Antineoplastic agents, 122. Constituents of Combretum caffrum

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Antineoplastic agents. 379. Synthesis of phenstatin phosphate

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

A new family of quinoline and quinoxaline analogues of combretastatins.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Recent advances in the field of tubulin polymerization inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Vascular occlusion and tumour cell death

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Antivascular therapy of cancer: DMXAA.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

The biology of the combretastatins as tumour vascular targeting agents

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700)

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Red blood cell behavior at low flow rate in microvessels

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Cytoskeletal regulation of pulmonary vascular permeability

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Regulation of vascular permeability by vascular endothelial growth factors.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Pharmacokinetic changes induced by vasomodulators in kidneys, livers, muscles, and implanted tumors in rats as measured by dynamic Gd-DTPA-enhanced MRI

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Rho GTPases and the regulation of endothelial permeability

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase)

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Microtubule disassembly increases endothelial cell barrier dysfunction: role of MLC phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Myosin light-chain kinase of smooth muscle stimulates myosin ATPase activity without phosphorylating myosin light chain

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Serotonin induced actin polymerization and association with cytoskeletal elements in cultured bovine aortic endothelium

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

In vivo targets of recombinant human tumour necrosis factor-alpha: blood flow, oxygen consumption and growth of isotransplanted rat tumours

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Endothelial-cell proliferation in experimental tumours

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Hypoxia/aglycemia increases endothelial permeability: role of second messengers and cytoskeleton

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Tumor necrosis factor-alpha-induced TRPC1 expression amplifies store-operated Ca2+ influx and endothelial permeability

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Microvascular permeability

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Role of Ca2+ signaling in the regulation of endothelial permeability

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Cadherins as modulators of angiogenesis and the structural integrity of blood vessels

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Vascular targeting agents as cancer therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Combretastatin A4 phosphate: background and current clinical status

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Phase I trial of combretastatin a-4 phosphate with carboplatin

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Delivery of molecular medicine to solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Synergy between vascular targeting agents and antibody-directed therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Tumor response to radiotherapy regulated by endothelial cell apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Targeting the tumor vasculature: a strategy to improve radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Expression of alpha-smooth muscle actin in benign or malignant ovarian tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Openings between defective endothelial cells explain tumor vessel leakiness

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Transport of molecules across tumor vasculature

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Causes and effects of heterogeneous perfusion in tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Intracapillary oxyhemoglobin saturation of malignant tumors in humans

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

31 March 2020

Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/NRC1628

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36146900&oldid=2198268497"